

**Testimony of the Board of Pharmacy**  
**Before the**  
**House Committee on Commerce Protection and Commerce**

**Wednesday, March 20, 2019**  
**2:00 p.m.**  
**State Capitol, Conference Room 329**

**On the following measure:**  
**S.B. 540, S.D. 1, H.D. 1, RELATING TO THE BOARD OF PHARMACY**

Chair Takumi and Members of the Committee:

My name is Lee Ann Teshima, and I am the Executive Officer of the Board of Pharmacy (Board). The Board supports this bill with the recommendation that its effective date be changed from July 1, 2050, to “upon approval.”

This bill proposes to allow the Board to approve pilot and demonstration projects for innovative applications in the practice of pharmacy under certain circumstances. This, in turn, will enhance the pharmacist’s ability to provide more patient-centered services.

During the summer, the Board established the Pharmacy Working Group (Group), which consisted of major stakeholders in the pharmacy industry, including, but not limited to, representatives from both local independent and chain store pharmacies, the medical community, and insurance groups. In particular, the Group discussed legislation introduced during the 2018 legislative session, including those measures that were enacted as law, those that did not pass, and other measures that affected the pharmacy scope of practice.

For the Committee’s information, one of the many topics discussed was the use of receptacles to allow pharmacies to participate in the national drug take-back initiative. Although this bill ultimately did not pass, the Group discussed how this project could benefit the public, as drug take-back is critical to ensuring the safe disposal of drugs. The Group also reviewed the laws of several states that allow pilot and demonstration research projects to be approved by the Board, including Virginia and California. The following is a short list of some of the pilot projects California and Virginia Boards of Pharmacy approved:

- In 2008, the California State Board of Pharmacy approved an E-Prescribing Pilot Project to determine the feasibility of, benefits of, and barriers to e-prescribing by a select group of Medi-Cal providers located in Los Angeles County. The goals were to improve patient safety, enhance prescribing process efficiency, reduce costs, and increase provider satisfaction. The Board has attached to this testimony the survey and utilization results of this pilot project.
- In 2013, the Virginia Board of Pharmacy initiated a pilot program that allowed persons to obtain prescription naloxone to administer to family members or friends to counteract opiate overdoses.

Thank you for the opportunity to testify on this bill.

# Survey & Utilization Results



## Patient Safety

- 91% of providers believed e-Rx reduced pharmacy calls from illegible handwriting
- Alerts made providers aware of potential drug-drug interactions & drug allergies
- Providers reported the number of Adverse Drug Events dropped from 53 to 39

## Factors Affecting Prescribing Process

- Significant reduction time spent on pharmacy calls regarding illegible handwriting (-3 min.,  $p=0.0104$ ) & dosing changes (-1.83 min.,  $p=0.0162$ )
- 67% believed the e-Rx renewal feature saved provider and staff time
- But increased time spent on pharmacy calls regarding formulary clarification & prior authorizations

## Costs Impact

- Increased generic utilization rate from 65% to 78% ( $p=0.013$ ,  $n=20$ )

For a Healthy Life



# UNIVERSITY OF HAWAII SYSTEM

## Legislative Testimony

---

Testimony Presented Before the  
House Committee on Consumer Protection & Commerce  
Wednesday, March 20, 2019 at 2:15 p.m., Rm 329

by

Marcia Sakai

Interim Chancellor

and

Carolyn Ma, PharmD, BCOP

Dean

Daniel K. Inouye College of Pharmacy  
University of Hawai'i at Hilo

### SB 540 SD1 HD1 – RELATING TO BOARD OF PHARMACY

Chair Takumi, Vice Chair Ichiyama, and members of the committee:

My name is Carolyn Ma and I am the Dean for the Daniel K. Inouye College of Pharmacy (DKICP). The DKICP supports this bill that will allow the board of pharmacy to approve pilot and demonstration projects for innovative applications in the practice of pharmacy.

As the only accredited College of Pharmacy in the state and the Pacific Rim, the DKICP's mission is to provide cutting edge and progressive healthcare to our community through education, research and service. Our faculty are trained to the highest degree of expertise and the concepts of innovation and discovery are the keystones of our ability to advance the pharmacy profession. The most advanced teaching methods are employed with a progressive and dynamic curriculum.

Approximately 30% of the Doctor of Pharmacy curriculum is experiential based where our students, through their four years in the program will practice as student pharmacists under the mentorship of our Pharmacy Practice faculty. These faculty clinical pharmacists are placed into most health care hospitals and clinics on the four major islands of Hawai'i, O'ahu, Maui and Kaua'i with the primary responsibility to, via their practice site, teach our students in the clinical setting and to advance the professions level of pharmacy practice within the institution. As the academic arm of the pharmacy profession, we partner with our health care institutions and other health care professionals to study, assess and evaluate innovative pharmacy practice patient care delivery models, technological medication distribution models and safety. Continued study to gain knowledge and data from pilot projects help us to seek advances may help to address the rising demands of complex patient care. Many of the registered pharmacists that practice in hospitals, clinics and community retail pharmacy sites also mentor or precept our students.

This bill will allow projects to lawfully proceed and keep the Board of Pharmacy informed of projects. These projects may be important to address needed changes and support a more progressive and current set of administrative rules.

Thank you for the opportunity to testify.

Testimony of  
Jonathan Ching  
Government Relations Specialist

Before:  
House Committee on Consumer Protection & Commerce  
The Honorable Roy M. Takumi, Chair  
The Honorable Linda Ichiyama, Vice Chair

March 20, 2019  
2:15 p.m.  
Conference Room 329

**Re: SB540, SD1, HD1, Relating to the Board of Pharmacy**

Chair Takumi, Vice-Chair Ichiyama, and committee members, thank you for this opportunity to provide testimony on SB540, SD1, HD1, which permits the Hawai'i State Board of Pharmacy to approve pilot and demonstration projects for innovative applications in the practice of pharmacy under certain circumstances.

**Kaiser Permanente Hawai'i SUPPORTS SB540, SD1, HD1.**

Kaiser Permanente Hawai'i is Hawai'i's largest integrated health system that provides care and coverage for nearly 255,000 members. Each day, more than 4,500 dedicated employees and more than 550 Hawai'i Permanente Medical Group physicians come to work at Kaiser Permanente Hawai'i to care for our members at Moanalua Medical Center and our 27 medical clinics, providing high-quality care for our members and delivering on our commitment to improve the health of the 1.4 million people living in the communities we serve.

Kaiser Permanente Hawai'i believes in continuously improving the effectiveness of health care delivery systems, including pharmacies. One way to accomplish that objective is to utilize new technologies which enable health care personnel to reallocate health tasks to better and more efficiently meet the health needs of the citizenry. We note that SB540, SD1, HD1 appears to be modeled after the Texas Pharmacy Act in which the Texas State Board of Pharmacy has considered projects for review that expand pharmaceutical care services and contribute to positive patient outcomes. Many of these projects have gone on to be implemented because they aid pharmacist's ability to provide more patient-centered services.

Therefore, we believe that authorizing the Board of Pharmacy to approve pilot and demonstration research projects can accelerate innovation and create opportunities for pharmacists to enhance patient care and safety, reduce barriers, and increase access to pharmaceutical services.

Mahalo for the opportunity to testify on this important measure.

SB540 – Allowing the Board of Pharmacy to approve and allow pilot demonstration projects.

Pharmacare Hawaii supports SB540 to allow the Board of Pharmacy to approve pilot demonstration projects for innovative applications in the practice of pharmacy. This ACT will help to improve patient access to care and improve their health outcomes with services that are innovative and currently restricted by regulations.

Technology has made it possible to do much more and be of much greater service to patients receiving medication therapy projects and services.



**SanHi**

GOVERNMENT STRATEGIES

A LIMITED LIABILITY LAW PARTNERSHIP

DATE: March 19, 2019

TO: Representative Roy Takumi  
Chair, House Committee on Consumer Protection and Commerce  
*Submitted Via Capitol Website*

FROM: Mihoko Ito

RE: **S.B. 540, S.D.1, H.D.1 – Relating to The Board of Pharmacy**  
**Hearing Date: Wednesday, March 20, 2019 at 2:15 p.m.**  
**Conference Room: 329**

---

Dear Chair Takumi and Members of the Committee:

We submit this testimony on behalf of Walgreen Co. (“Walgreens”). Walgreens operates stores at more than 8,200 locations in all 50 states, the District of Columbia, and Puerto Rico. In Hawaii, Walgreens now has 19 stores on the islands of Oahu, Maui, and Hawaii.

Walgreens **supports S.B. 540, S.D.1, H.D.1.** This bill allows the board of pharmacy to approve pilot and demonstration projects for innovative applications in the practice of pharmacy under certain circumstances.

Walgreens supports the idea of pilot projects that could enhance patient care via the use of new technologies and believes that this bill would be a beneficial way to test innovation and demonstration projects.

We are also supportive of the amendment made in the Senate to delete language including drug take back programs from pilot projects, since these programs are already strictly regulated at the federal level by the Drug Enforcement Agency.

Thank you for the opportunity to submit testimony regarding this measure.

**SB-540-HD-1**

Submitted on: 3/15/2019 10:27:02 PM

Testimony for CPC on 3/20/2019 2:15:00 PM

| Submitted By                  | Organization | Testifier<br>Position | Present at<br>Hearing |
|-------------------------------|--------------|-----------------------|-----------------------|
| Ronald Taniguchi,<br>Pharm.D. | Individual   | Support               | No                    |

Comments: